David Rog

3.6k citations

62 papers · 1.4k indexed · 1 hit paper · h-index 16

Impact in

Pharmacology top 2%
- Cannabis and Cannabinoid Research
Pathology and Forensic Medicine top 2%
- Multiple Sclerosis Research Studies

Papers in ⓘ

Pathology and Forensic Medicine 39
- Multiple Sclerosis Research Studies 39
Neurology 9

Co-authors: Carolyn Young (16 shared papers)Turo Nurmikko (4 shared papers)Tim Friede (2 shared papers)Owen Pearson (8 shared papers)Richard Nicholas (10 shared papers)Nick S. Jones (1 shared paper)Chris McGuigan (1 shared paper)Paul Molyneux (1 shared paper)
Journals: Multiple Sclerosis and Related Disorders (16 papers)Multiple Sclerosis Journal (7 papers)Neurology (6 papers)Journal of Neurology Neurosurgery & Psychiatry (6 papers)Journal of the Neurological Sciences (3 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

David Rog

59 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis 2005 · 504 citations

Peers

Countries citing papers authored by David Rog

Since Specialization

Citations

This map shows the geographic impact of David Rog's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Rog with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Rog more than expected).

Fields of papers citing papers by David Rog

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Rog. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Rog. The network helps show where David Rog may publish in the future.

Co-authors

The 25 scholars most cited alongside David Rog, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Rog Line = papers co-authored together David Rog links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis Neurology ·David Rog, Turo Nurmikko, Tim Friede, Carolyn Young Hit paper breakdown →	2005	504
2	Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group Journal of Neurology Neurosurgery & Psychiatry ·Chris McGuigan, M Craner, Joseph V. Guadagno, Raj Kapoor, Gordon Mazibrada, Paul Molyneux, Richard Nicholas, Jacqueline Palace, Owen Pearson, David Rog, Carolyn Young	2015	168
3	Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial Clinical Therapeutics ·David Rog, Turo Nurmikko, Carolyn Young	2007	157
4	Olfaction: a review The Journal of Laryngology & Otology ·Nick S. Jones, David Rog	1998	41
5	Validation and Reliability of the Neuropathic Pain Scale (NPS) in Multiple Sclerosis Clinical Journal of Pain ·David Rog, Turo Nurmikko, Tim Friede, Carolyn Young	2007	37
6	COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies Multiple Sclerosis and Related Disorders ·Afagh Garjani, Rod Middleton, Rachael Hunter, Katherine Tuite-Dalton, Alasdair Coles, Ruth Dobson, Martin Duddy, Stella Hughes, Owen Pearson, David Rog, Emma Tallantyre, Roshan das Nair, Richard Nicholas, Nikos Evangelou	2021	36
7	Inequalities in access to health and social care among adults with multiple sclerosis: A scoping review of the literature Multiple Sclerosis and Related Disorders ·Hazel Roddam, David Rog, Jessie Janssen, Neil Wilson, Lucy Cross, Olufemi Olajide, Paola Dey	2019	34
8	Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy Journal of the Neurological Sciences ·Carolyn Young, Roger Mills, David Rog, Basil Sharrack, Tahir Majeed, Cris S. Constantinescu, Seema Kalra, Timothy Harrower, Helen Santander, Gillian Courtald, Helen Ford, John Woolmore, Alan Tennant	2021	31
9	Cannabis-based medicines in multiple sclerosis – A review of clinical studies Immunobiology ·David Rog	2010	28
10	Use of coping strategies in multiple sclerosis: Association with demographic and disease-related characteristics✰ Multiple Sclerosis and Related Disorders ·David Holland, Daniela K Schlüter, Carolyn Young, R. J. Mills, David Rog, Helen Ford, Kim Orchard	2018	27
11	Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry Neurology Neuroimmunology & Neuroinflammation ·Kerstin Hellwig, David Rog, Christopher McGuigan, Maria K. Houtchens, Denise R. Bruen, Oksana Mokliatchouk, Filipe Branco, Xiaomei Peng, Nicholas Everage	2021	27
12	Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines Practical Neurology ·Ruth Dobson, David Rog, Caroline Ovadia, Katy Murray, Stella Hughes, Helen Ford, Owen Pearson, Sarah J. White, Nicola Bonham, Joela Mathews, Catherine Nelson‐Piercy, Peter Brex	2022	24
13	Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case–control study of the UK MS Register Multiple Sclerosis Journal ·Afagh Garjani, Rachael Hunter, Graham Law, Rod Middleton, Katherine Tuite-Dalton, Ruth Dobson, David Ford, Stella Hughes, Owen Pearson, David Rog, Emma Tallantyre, Richard Nicholas, Richard Morriss, Nikos Evangelou, Roshan das Nair	2021	20
14	Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis Multiple Sclerosis and Related Disorders ·Keh Yann, Fran Jackson, Nazar Sharaf, Tatiana Mihalova, Paul Talbot, David Rog, Adrian Pace	2017	20
15	Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years Multiple Sclerosis and Related Disorders ·Jiwon Oh, Anat Achiron, Elisabeth Gulowsen Celius, Christina Chambers, Joy Derwenskus, Virginia Devonshire, Kerstin Hellwig, George J. Hutton, Pamela McCombe, Marie Moore, David Rog, Jean-Raphael Schneider, Renata Simm, Lívia Sousa, Stephen G. Vincent, Luke Chung, Nadia Daizadeh, Colin Mitchell, D. A. S. Compston	2020	20
16	Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: A qualitative interview study Multiple Sclerosis and Related Disorders ·Elaine Cameron, David Rog, Gavin McDonnell, James Overell, Owen Pearson, David French	2018	17
17	A Systematic Review of Resting-State Functional MRI Connectivity Changes and Cognitive Impairment in Multiple Sclerosis Brain Connectivity ·Danka Jandric, Anisha Doshi, Richelle Scott, David Paling, David Rog, Jeremy Chataway, Menno M. Schoonheim, Geoff J.M. Parker, Nils Muhlert	2021	15
18	Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years Multiple Sclerosis and Related Disorders ·Ann Bass, Rafael Arroyo, Aaron Boster, Alexey Boyко, Sara Eichau, Carolina Ionete, Volker Limmroth, Cárlos Navas, Daniel Pelletier, Carlo Pozzilli, Jennifer Ravenscroft, Lívia Sousa, Mar Tintoré, Bernard M.J. Uitdehaag, Darren P. Baker, Nadia Daizadeh, Zia Choudhry, David Rog	2020	15
19	Patient expectations and experiences of multiple sclerosis interferon ß-1a treatment: a longitudinal, observational study in routine UK clinical practice Patient Preference and Adherence ·Mehmood Syed, David Rog, Parkes, Gillian Shepherd	2014	12
20	Measuring disability in multiple sclerosis: the WHODAS 2.0 Quality of Life Research ·Carolyn Young, David Rog, Basil Sharrack, Cris S. Constantinescu, Seema Kalra, Timothy Harrower, Dawn Langdon, Alan Tennant, Roger Mills, (unknown)	2023	11

About David Rog

David Rog is a scholar working on Pathology and Forensic Medicine, Neurology, Public Health, Environmental and Occupational Health, Immunology and Obstetrics and Gynecology, having authored 62 papers that have together received 1.4k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (39 papers), Pregnancy and Medication Impact (10 papers), Polyomavirus and related diseases (8 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers), Reproductive System and Pregnancy (6 papers), Cannabis and Cannabinoid Research (5 papers), Acute Lymphoblastic Leukemia research (5 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). The work is most often cited by research in Pharmacology (561 citations), Pathology and Forensic Medicine (572 citations), Neurology (274 citations), Toxicology (54 citations) and Sensory Systems (51 citations). David Rog has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Carolyn Young, Turo Nurmikko, Tim Friede, Owen Pearson, Richard Nicholas, Nick S. Jones, Chris McGuigan, Paul Molyneux, Raj Kapoor and Jacqueline Palace. Their work appears in journals such as Multiple Sclerosis and Related Disorders, Multiple Sclerosis Journal, Neurology, Journal of Neurology Neurosurgery & Psychiatry and Journal of the Neurological Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact